Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Apr;29(4):431–436. doi: 10.1111/j.1365-2125.1990.tb03661.x

Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man.

J M Ritter 1, N Benjamin 1, H S Doktor 1, S E Barrow 1, T G Mant 1, S Schey 1, P Stewart-Long 1
PMCID: PMC1380113  PMID: 2139338

Abstract

1. GR32191B is a potent and selective thromboxane receptor antagonist. Glyceryl trinitrate (GTN) also inhibits platelet function in vitro. Both have been reported to prolong bleeding time. Since they may be used together in patients with coronary artery disease, we have investigated the possibility of an interaction between them. 2. Twenty-four healthy male volunteers were treated with GR32191B using a double-blind placebo-controlled crossover design. Bleeding times were determined before and after GR32191B or placebo and during co-administration of GTN. Plasma GR32191B concentration was measured. Platelet aggregation in response to adenosine diphosphate and to a thromboxane mimetic, U46619, was measured ex vivo. Urinary excretion of thromboxane (TX)B2 and 2,3-dinor-TXB2 was determined in 24 h urine samples. 3. Twelve hours after GR32191B (80 mg; p.o.), the plasma concentration was 36.6 +/- 2.7 nM (mean +/- s.e. mean) and bleeding time was increased by 66%. Ninety minutes after a second dose (40 mg; p.o.) the plasma concentration was 431.9 +/- 23.6 nM but bleeding time was not further prolonged. 4. Responses of platelets to U46619 were selectively antagonised following GR32191B. Urinary excretion rates of TXB2 and 2,3-dinor TXB2 were similar after treatment with GR32191B or placebo. 5. GTN (1 mg sub-lingually) had no significant effect on bleeding time 90-100 min following either placebo or GR32191B. 6. We conclude that GR32191B, in a dose that causes profound yet specific blockade of thromboxane receptors, causes only a modest prolongation of bleeding time that is unaffected by a therapeutic dose of GTN. This may prove advantageous when GR32191B is used in patients with ischaemic heart disease.

Full text

PDF
431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babson S. R., Babson A. L. Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations. Am J Clin Pathol. 1978 Sep;70(3):406–408. doi: 10.1093/ajcp/70.3.406. [DOI] [PubMed] [Google Scholar]
  2. Barrow S. E., Ward P. S., Sleightholm M. A., Ritter J. M., Dollery C. T. Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. Biochim Biophys Acta. 1989 Oct 13;993(1):121–127. doi: 10.1016/0304-4165(89)90151-7. [DOI] [PubMed] [Google Scholar]
  3. Bick R. L., Adams T., Schmalhorst W. R. Bleeding times, platelet adhesion, and aspirin. Am J Clin Pathol. 1976 Jan;65(1):69–72. doi: 10.1093/ajcp/65.1.69. [DOI] [PubMed] [Google Scholar]
  4. Chiabrando C., Benigni A., Piccinelli A., Carminati C., Cozzi E., Remuzzi G., Fanelli R. Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. Anal Biochem. 1987 May 15;163(1):255–262. doi: 10.1016/0003-2697(87)90121-7. [DOI] [PubMed] [Google Scholar]
  5. Feelisch M., Noack E. A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol. 1987 Jul 2;139(1):19–30. doi: 10.1016/0014-2999(87)90493-6. [DOI] [PubMed] [Google Scholar]
  6. FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., 2nd, Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676–688. doi: 10.1172/JCI110814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fitzgerald D. J., Roy L., Robertson R. M., FitzGerald G. A. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation. 1984 Aug;70(2):297–302. doi: 10.1161/01.cir.70.2.297. [DOI] [PubMed] [Google Scholar]
  8. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hammarström S., Falardeau P. Resolution of prostaglandin endoperoxide synthase and thromboxane synthase of human platelets. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3691–3695. doi: 10.1073/pnas.74.9.3691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hampton J. R., Harrison M. J., Honour A. J., Mitchell J. R. Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res. 1967 Apr;1(2):101–107. doi: 10.1093/cvr/1.2.101. [DOI] [PubMed] [Google Scholar]
  11. Le Breton G. C., Venton D. L., Enke S. E., Halushka P. V. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4097–4101. doi: 10.1073/pnas.76.8.4097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lefer A. M., Darius H. A pharmacological approach to thromboxane receptor antagonism. Fed Proc. 1987 Jan;46(1):144–148. [PubMed] [Google Scholar]
  13. Lichtenthal P. R., Rossi E. C., Louis G., Rehnberg K. A., Wade L. D., Michaelis L. L., Fung H. L., Patrignani P. Dose-related prolongation of the bleeding time by intravenous nitroglycerin. Anesth Analg. 1985 Jan;64(1):30–33. [PubMed] [Google Scholar]
  14. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985 Aug;76(2):703–708. doi: 10.1172/JCI112024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lumley P., White B. P., Humphrey P. P. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989 Jul;97(3):783–794. doi: 10.1111/j.1476-5381.1989.tb12017.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mellion B. T., Ignarro L. J., Ohlstein E. H., Pontecorvo E. G., Hyman A. L., Kadowitz P. J. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981 May;57(5):946–955. [PubMed] [Google Scholar]
  17. Mielke C. H., Jr, Kaneshiro M. M., Maher I. A., Weiner J. M., Rapaport S. I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969 Aug;34(2):204–215. [PubMed] [Google Scholar]
  18. Nicolaou K. C., Magolda R. L., Smith J. B., Aharony D., Smith E. F., Lefer A. M. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2566–2570. doi: 10.1073/pnas.76.6.2566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Patrono C., Ciabattoni G., Remuzzi G., Gotti E., Bombardieri S., Di Munno O., Tartarelli G., Cinotti G. A., Simonetti B. M., Pierucci A. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest. 1985 Sep;76(3):1011–1018. doi: 10.1172/JCI112053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Radomski M. W., Palmer R. M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987 Nov;92(3):639–646. doi: 10.1111/j.1476-5381.1987.tb11367.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ring T., Knudsen F., Kristensen S. D., Larsen C. E. Nitroglycerin prolongs the bleeding time in healthy males. Thromb Res. 1983 Mar 15;29(6):553–559. doi: 10.1016/0049-3848(83)90210-4. [DOI] [PubMed] [Google Scholar]
  22. Ritter J. M., Barrow S. E., Smith P. L., Taylor K. M., Dollery C. T. Predominance of locally-produced prostaglandin E2 over prostacyclin in skin incisions in man. Prostaglandins. 1987 Dec;34(6):867–875. doi: 10.1016/0090-6980(87)90067-0. [DOI] [PubMed] [Google Scholar]
  23. Ritter J. M., Dollery C. T. Therapeutic opportunities in vasoocclusive disease. Circulation. 1986 Feb;73(2):240–243. doi: 10.1161/01.cir.73.2.240. [DOI] [PubMed] [Google Scholar]
  24. Schafer A. I., Alexander R. W., Handin R. I. Inhibition of platelet function by organic nitrate vasodilators. Blood. 1980 Apr;55(4):649–654. [PubMed] [Google Scholar]
  25. Synek P., Rysánek K., Spánková H., Mlejnková M. The effect of ethanol and nitroglycerin on platelet aggregation. Act Nerv Super (Praha) 1970 Jan 12;12(1):77–78. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES